Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is taken once a week — not twice, not daily. Whether you're using Wegovy as a weekly injection or the newer Wegovy tablet, the dosing interval is always seven days, and taking it more frequently than that doesn't increase its effectiveness; it raises your risk of side effects. Semaglutide has a long half-life by design, which means one dose sustains therapeutic levels in your body across the full week. These are prescription-only medicines, so the exact schedule your prescriber sets (starting dose, timing, and any adjustments) is what you should follow, not a general rule you've read online.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That moment of doubt is something our prescribers hear about most weeks. You're not forgetful; it's just that a once-weekly routine is genuinely easy to lose track of, especially in the first month. The short answer: semaglutide is taken once every seven days. That's the full dosing schedule for Wegovy as a subcutaneous injection, and the licensed interval hasn't changed with the introduction of higher doses. The medicine's pharmacokinetics (the way it's absorbed, distributed, and cleared) were built around that weekly interval.
What that means practically is that semaglutide accumulates to a steady level in your system after several weeks of consistent weekly dosing. Injecting a second dose mid-week to 'top up' doesn't deliver more benefit; semaglutide's receptor binding doesn't work that way. It would, however, stack the dose and significantly increase your chance of nausea, vomiting, or more serious side effects. So the answer to 'can I take it twice a week' is simply: no, and your prescriber will tell you the same. For a fuller picture of what Wegovy is and how it works, the Wegovy overview at nume covers the mechanism and the licensed dose ladder clearly.
The question of how often to take Wegovy comes up precisely because people want to do it right. Sticking to the weekly day you choose (same day, every week) is the most reliable approach.
Since the MHRA approved oral semaglutide (Wegovy tablets) in June 2026, 'how many times a week can you take semaglutide' has started to mean something slightly different for some people. The tablet is taken once daily, every day, not once a week. That shift in frequency is the most important practical difference between the two formulations, the active ingredient is the same semaglutide; the delivery system changes how often you take it.
The daily tablet is swallowed first thing in the morning, on an empty stomach, with a small amount of plain water (no more than around 120ml) and then you wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. That window matters because semaglutide's absorption through the gut lining depends on the right conditions. Miss the window and you've effectively reduced that day's dose.
The dose schedule escalates from 1.5mg through 4mg and 9mg up to a 25mg maintenance dose, with a minimum of one month at each level. You can read more about who semaglutide is suitable for and the clinical criteria a prescriber will consider. If you're already established on the 2.4mg weekly injection and your prescriber is discussing switching to the tablet, that transition is also a clinical decision, it's not simply a swap.
It happens. Life gets in the way, pens get left at a friend's house, or you simply forget which day you last injected. The key thing to know is that semaglutide's long half-life gives you some flexibility that a daily medicine wouldn't. If you're late by a day or two, you don't need to double up; you take the dose when you remember, then carry on from that new day as your weekly anchor.
If you've missed a full week, the guidance gets more specific, and 'more specific' is exactly why this page isn't the right place to give you a definitive answer. The late-dose guidance for Wegovy goes into this in detail, and the Patient Information Leaflet that came with your pen is the authoritative source. Some people worry that a missed week means starting over from scratch; others wonder about taking a deliberate break. If a planned pause is what you're considering, there's dedicated information on whether taking a week off Wegovy is advisable.
What a prescriber will tell you consistently is this: don't try to compensate with a double dose. The body doesn't absorb or benefit from twice the amount in one go; it's more likely to make you feel unwell. Report any concerns to your clinical team rather than improvising the schedule. The NHS medicines information for semaglutide at nhs.uk covers missed doses in patient-friendly language and is a reliable first reference.
The reason this question has a firm, non-negotiable answer is rooted in how the medicine was developed and licensed. The SURMOUNT and STEP trials that informed regulators (including the STEP 1 trial published in the New England Journal of Medicine) were built entirely around once-weekly subcutaneous semaglutide at 2.4mg, with a structured titration over 16–20 weeks. The safety and efficacy data that the MHRA and NICE assessed relates to that dosing interval. Deviating from it isn't just a scheduling preference; it moves you outside the conditions under which the medicine was shown to be safe and effective.
That matters because these are prescription-only medicines. The clinical assessment you go through before a prescription is issued isn't a formality; a GPhC-registered prescriber reviews your answers, your weight, and your medical history. That same oversight applies at every repeat. If you're unsure whether your current schedule is right, or if something in your circumstances has changed, speaking to your prescribing team is straightforward. You can find out more about how many people are currently using semaglutide in the UK and the broader context of its use. For anyone considering starting treatment, speaking to our prescribers is the natural next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.